# Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

> **NCT00135096** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 345 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin glulisine
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00135096
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135096, "Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00135096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*